Asthma Refills

Yes. California Business and Professions Code Section 2290.5 permits licensed physicians to deliver care and prescribe appropriate medications via synchronous video telehealth without a prior in-person visit. TeleDirectMD\'s California-licensed board-certified Family Medicine physician reviews your current asthma regimen — including your ICS, ICS+LABA, rescue inhaler usage, and ACT score — and can authorize refills for stable established asthma. Self pay is $49; Aetna commercial plans are in-network effective April 30, 2026.

TeleDirectMD can refill established asthma controller regimens including inhaled corticosteroids (ICS) such as fluticasone and budesonide, ICS+LABA combination inhalers such as budesonide/formoterol (Symbicort) and fluticasone/salmeterol (Advair), leukotriene receptor antagonists (montelukast), and albuterol rescue inhalers. The physician reviews GINA 2024 stepwise criteria to confirm the current regimen remains appropriate. Biologic therapies (dupilumab, benralizumab, mepolizumab) require specialist management — TeleDirectMD will facilitate an allergist or pulmonologist referral.

California wildfire smoke events significantly increase PM2.5 exposure and drive asthma exacerbations statewide, per the California Air Resources Board. The TeleDirectMD physician reviews recent air quality conditions in your area, the California AQI, and your symptom pattern before authorizing refills. If wildfire smoke has worsened your asthma control, the physician may adjust your step therapy — for example, temporarily increasing ICS dose or adding a course of oral corticosteroids — before renewing the standard regimen.

TeleDirectMD is not currently enrolled as a Medi-Cal provider, so Medi-Cal will not cover TeleDirectMD visits. However, Medi-Cal\'s formulary does cover asthma controller inhalers including budesonide and generic formulations. If you have Medi-Cal, you can use TeleDirectMD\'s $49 self-pay rate or seek a Medi-Cal-enrolled primary care provider for your refills. Visit dhcs.ca.gov for the Medi-Cal provider directory.

The Global Initiative for Asthma (GINA) 2024 stepwise framework organizes asthma treatment into Steps 1–5 based on symptom frequency, nighttime awakenings, rescue inhaler use, and FEV1. Step 1 uses as-needed SABA or low-dose ICS PRN for mild intermittent asthma. Steps 2–3 add daily ICS or ICS+LABA for persistent disease. Steps 4–5 escalate to higher-dose combination therapy, and Step 5 involves biologic therapy for uncontrolled severe asthma. The physician reviews your current step and the Asthma Control Test (ACT) score at every refill visit.

Seek emergency care immediately for severe dyspnea at rest, inability to speak full sentences, oxygen saturation below 92%, accessory muscle use, rapid worsening not responding to repeated rescue inhaler use, or silent chest. Use urgent care for moderate exacerbations with incomplete relief after 2–3 albuterol treatments. TeleDirectMD is appropriate for stable asthma refills and mild symptom changes — not for acute exacerbations.

Aetna became an active in-network payor for TeleDirectMD in California effective April 30, 2026. If you hold an Aetna commercial plan in California, you may be able to use your in-network benefits for your asthma refill visit. Always verify current in-network status with Aetna before booking, as plan eligibility varies by specific plan type. See the Aetna × California coverage details page for more information.

The TeleDirectMD physician reviews: current symptom control (ACT score or validated equivalent), rescue inhaler use frequency (more than 2 days/week indicates poor control), nighttime awakenings, activity limitation, oral corticosteroid courses in the past year, ER or urgent care visits for asthma, spirometry or peak flow history if available, and any environmental exposures including wildfire smoke. Refills are authorized for patients with stable, well-controlled asthma consistent with GINA 2024 criteria.

Yes, montelukast is a leukotriene receptor antagonist (LTRA) approved as an alternative Step 2 controller for mild persistent asthma and as adjunct therapy. The FDA issued a boxed warning for montelukast in 2020 regarding neuropsychiatric adverse events including suicidality. The TeleDirectMD physician reviews this warning with you and documents informed consent before prescribing. Montelukast is generally reserved for patients who cannot use ICS or as adjunct to ICS.

California AB 744 (2019), codified in Insurance Code §10123.85, requires commercial health plans to reimburse telehealth services on the same basis as in-person services. Parity applies only when TeleDirectMD is already in-network with your specific plan. Currently, Aetna commercial (active April 30, 2026) and UnitedHealthcare Commercial (active May 29, 2026) are in-network in California. Anthem Blue Cross and Cigna enrollments are pending.

GoodRx coupon pricing for common asthma medications in California (May 2026): albuterol HFA approximately $30–$60 per inhaler; fluticasone propionate HFA approximately $45–$100; budesonide/formoterol (Symbicort) approximately $60–$160; fluticasone/salmeterol (Advair) approximately $60–$180; generic montelukast 10 mg approximately $15–$25 per month. Prices vary by pharmacy and dose. The TeleDirectMD visit fee ($49) covers evaluation only — inhaler costs are separate.

If your asthma is worsening despite your current controller regimen, a video visit may be appropriate for step-up assessment, short oral corticosteroid course authorization, and facilitation of an allergist or pulmonologist referral. However, if you have an acute exacerbation with significant dyspnea, go to urgent care or the ER. Do not use TeleDirectMD for emergencies.